Cassava Sciences’ Alzheimer’s Drug Fails in Clinical Trial, Stock Plummets

Clinical Trial Failure:
The ReThink-ALZ study conducted by Cassava Sciences failed to meet its co-primary endpoints, showing no significant improvement in cognition or daily functioning in Alzheimer's patients after 52 weeks[1][2].

Stock Decline:
Following the announcement of the trial's failure, Cassava Sciences' stock plummeted by 85%, marking its largest one-day decline[3].

Controversy Surrounding Research:
The drug's development was already controversial due to allegations of fraudulent images in basic research studies used to justify clinical trials[2].

Impact on Alzheimer's Research:
The failure of Cassava Sciences' drug is a setback in the search for effective treatments for Alzheimer's disease, highlighting the challenges in developing successful therapies for this complex condition.